You are here: Industry Insights > Biogen

News List

Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
Biogen's Spinraza gets a boost from NICE as competitors loom fiercepharma
May 16, 2019
As analysts speculate about the future of Biogen’s pricey spinal muscular atrophy (SMA) treatment Spinraza, the company is hoping it can corner the market before competitors take the field.
American Academy of Neurology, May 4-10 drugs
May 15, 2019
American Academy of Neurology, May 4-10.
Biogen posts 20-percent increase in first-quarter profit, as Spinraza sales jump firstwordpharma
April 25, 2019
Biogen delivered strong financial results in the first quarter driven by the solid operational performance of our [multiple sclerosis], [spinal muscular atrophy] and biosimilars franchises ...
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen……
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen and Ionis Pharmaceuticals' spinal muscle atrophy (SMA) therapy Spinraza (nusinersen) is not cost-effective at its current price.
Eisai, Biogen move Alzheimer’s treatment into Phase III pharmatimes
March 27, 2019
Eisai and Biogen have announced that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401, for use in patients with early Alzheimer's disease.
Eisai, Biogen to advance Alzheimer's drug BAN2401 in Phase III testing following failure of aducanumab firstwordpharma
March 23, 2019
Eisai announced Friday that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401……
Biogen, Eisai scrap late-stage studies of aducanumab in Alzheimer's disease as deemed unlikely to hit main goals firstwordpharma
March 21, 2019
Biogen and Eisai said Thursday that Phase III studies of the experimental anti-amyloid beta antibody aducanumab ……
Fujifilm to acquire Biogen in a $890 M deal biospectrumasia
March 13, 2019
FUJIFILM Corporation ("Fujifilm") announced that it has entered into an agreement to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark ("Biogen Hillerød") from Biogen for ap

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page